Insmed (LTS:0JAV) Change In Inventory : $-19.4 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Insmed Change In Inventory?

Insmed's change in inventory for the quarter that ended in Sep. 2024 was $-6.6 Mil. It means Insmed's inventory increased by $6.6 Mil from Jun. 2024 to Sep. 2024 .

Insmed's change in inventory for the fiscal year that ended in Dec. 2023 was $-13.6 Mil. It means Insmed's inventory increased by $13.6 Mil from Dec. 2022 to Dec. 2023 .

Insmed's Total Inventories for the quarter that ended in Sep. 2024 was $98.5 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Insmed's Days Inventory for the quarter that ended in Sep. 2024 was 406.32.

Inventory Turnover measures how fast the company turns over its inventory within a year. Insmed's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.22.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Insmed's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 1.01.

Insmed Change In Inventory Historical Data

The historical data trend for Insmed's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Change In Inventory Chart

Insmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-21.28

-21.18

-17.46

-1.71

-13.61

Insmed Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Inventory	Get a 7-Day Free Trial															-1.10	-4.43	-0.60	-7.76	-6.57

Insmed Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.4 Mil.

Insmed (LTS:0JAV) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Insmed's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	94.2665	/	21.17	*	365 / 4
	=	406.32

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Insmed's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	21.17	/	94.2665
	=	0.22

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Insmed's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	94.2665	/	93.425
	=	1.01

Insmed Change In Inventory Related Terms

Thank you for viewing the detailed overview of Insmed's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (LTS:0JAV) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

INSM:USA IM8N:Germany IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Headlines

No Headlines